Kotaro Takeshita

Dr. Kotaro Takeshita

hepatobiliary and pancreatic oncology, National Cancer Centre, Tokyo, Japan
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2024 in Endoscopic Ultrasound
Verified
Journal Article
Open access
TOTakeshi Ogura
Takeshi Ogura
Susumu HijiokaSusumu Hijioka
Susumu Hijioka
KHKazuo WINDOW Hara Hara
Kazuo WINDOW Hara Hara
NNNobu Nishioka
Nobu Nishioka
AOAtsushi Okuda
Atsushi Okuda
NONozomi Okuno
Nozomi Okuno
Background and Objectives: According to previous reports, EUS–fine-needle biopsy (FNB) with or without rapid on-site evaluation (ROSE) showed the nonsuperiority of EUS-FNB + ROSE over EUS-FNB. However, previous studies included various kinds of FNB needle. This might be a critical limitation due to heterogeneity. Therefore, the aim of the present multicenter, randomized controlled trial was to compare the diagnostic accuracy of the fork-tip needle with or without ROSE for pancreatic lesions. Methods: In the ROSE group, if an adequate sample was obtained to diagnose by on-site evaluation, EUS-FNB was stopped. If cytological results were insufficient or indeterminate, EUS-FNB was repeated. In the macroscopic on-site evaluation (MOSE) group, if a 4-mm length of visible core tissue was obtained, EUS-FNB was finished. If visible core tissue was not obtained or was less than 4 mm in length, a second puncture was attempted. Results: One hundred seventy-one patients were randomized, 85 to the ROSE group and 86 to the MOSE group. In the MOSE group, diagnostic sensitivity and accuracy were 94.4% and 91.8%, respectively, for visible core tissue and 80.6% and 70.0%, respectively, for red tissue. Finally, overall diagnostic sensitivity and accuracy were 97.1% and 95.3%, respectively, in the ROSE group and 95.8% and 95.3%, respectively, in the MOSE group. Although there were no significant differences regarding adverse events between groups, the mean number of punctures was significantly lower in the MOSE group than in the ROSE group (1.47 vs. 1.20, P = 0.0171). Conclusions: EUS-FNB using a fork-tip needle for pancreatic lesions has high diagnostic yield even without ROSE.

3 July 2024 in Endoscopy International Open
Verified
Journal Article
Open access
PDF file
KTKotaro Takeshita
Kotaro Takeshita
Susumu HijiokaSusumu Hijioka
Susumu Hijioka
YNYoshikuni Nagashio
Yoshikuni Nagashio
YMYuta Maruki
Yuta Maruki
AOAkihiro Ohba
Akihiro Ohba
TOTakuji Okusaka
Takuji Okusaka
Background and study aims Endoscopic ultrasound-guided hepaticogastrostomy with bridging between the left and right bile ducts is an alternative to endoscopic transpapillary drainage for malignant hilar biliary obstruction. We aimed to analyze the long-term stent patency of endoscopic ultrasound-guided hepaticogastrostomy with bridging. Patients and methods Patients who underwent endoscopic ultrasound-guided hepaticogastrostomy with bridging between April 2018 and July 2023 were retrospectively analyzed. We retrospectively compared the stent patency of these patients with that of the individuals who underwent endoscopic transpapillary drainage-multi-stenting using unmatched (entire) and propensity score-matched cohorts. Results Endoscopic ultrasound-guided hepaticogastrostomy with bridging had a technical success rate of 90% (18/20). Adverse events were minimal. The number of clinical success cases was 17 and 82 for endoscopic ultrasound-guided hepaticogastrostomy with bridging using metallic stent and endoscopic transpapillary drainage-multi-stenting, respectively. The recurrent biliary obstruction rate was 17.6% and 58.5% for endoscopic ultrasound-guided hepaticogastrostomy with bridging and endoscopic transpapillary drainage-multi-stenting, respectively; the median time to recurrent biliary obstruction (days) was significantly longer for endoscopic ultrasound-guided hepaticogastrostomy with bridging in the entire (not reached vs. 104, P=0.03) and propensity score-matched (183 vs. 79, P=0.05) cohorts. The non-recurrent biliary obstruction rate for endoscopic ultrasound-guided hepaticogastrostomy with bridging was 91.6% at 3 and 6 months and 57% at 12 months. Multivariate analyses revealed that endoscopic ultrasound-guided hepaticogastrostomy with bridging contributed to a lower recurrent biliary obstruction incidence (hazard ratio, 0.31, P=0.05) without significant difference. Conclusions Stent patency was significantly better for endoscopic ultrasound-guided hepaticogastrostomy with bridging. However, future prospective studies are needed.

28 March 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
Susumu HijiokaSusumu Hijioka
Susumu Hijioka
YNYoshikuni Nagashio
Yoshikuni Nagashio
YMYuta Maruki
Yuta Maruki
YKYuki Kawasaki
Yuki Kawasaki
KTKotaro Takeshita
Kotaro Takeshita
Takuji OkusakaTakuji Okusaka
Takuji Okusaka
In recent years, cancer genomic medicine centered on comprehensive genome profile (CGP) analysis has become widely used in the field of pancreatic cancer. Endoscopic ultrasound-guided tissue acquisition (EUS-TA) has played an important role in pancreatic cancer, and recently, more EUS-TA tissue samples are considered for CGP analysis. Differences exist between the Oncoguide NCC Oncopanel System and Foundation One CDx Cancer Genome Profile, which are CGP tests approved by insurance programs in Japan, including the analysis criteria, optimal needle selection for meeting these criteria, and puncture target. It is important to understand not only the specimen collection factors, but also the specimen processing factors that can increase the success rate of CGP testing. Furthermore, cancer genome medicine is expected to enter an era of increasing turbulence in the future, and endoscopists need to respond flexibly to these changes. Herein, we review the current status of cancer genome medicine in pancreatic and biliary tract cancers and cancer gene panel testing using EUS-TA.

18 July 2024 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
TOTakeshi Ogura
Takeshi Ogura
HIHirotoshi Ishiwatari
Hirotoshi Ishiwatari
Susumu HijiokaSusumu Hijioka
Susumu Hijioka
KTKotaro Takeshita
Kotaro Takeshita
JSJunya Sato
Junya Sato
MKMasayuki Kitano
Masayuki Kitano

1 March 2024 in Endoscopic Ultrasound
Verified
Journal Article
Open access
YKYuki Kawasaki
Yuki Kawasaki
Susumu HijiokaSusumu Hijioka
Susumu Hijioka
YNYoshikuni Nagashio
Yoshikuni Nagashio
AOAkihiro Ohba
Akihiro Ohba
YMYuta Maruki
Yuta Maruki
Takuji OkusakaTakuji Okusaka
Takuji Okusaka
Background and Objectives: EUS tissue acquisition (EUS-TA) is the standard diagnostic method for solid pancreatic lesions (SPLs); however, there are few reports on EUS-TA results for SPLs ≤10 mm. Furthermore, given the recent advent of fine-needle biopsy, the current diagnostic accuracy of EUS-TA for SPLs ≤10 mm is unknown. This study aimed to evaluate the diagnostic accuracy and efficacy of EUS-TA for SPLs ≤10 mm. Methods: We retrospectively analyzed the data of 109 patients with SPLs ≤10 mm who underwent EUS-TA. All patients underwent rapid on-site specimen evaluation. Results: The median tumor diameter was 8 mm (range, 2.5–10 mm), and the technical success rate was 99.1% (108/109). Adverse events were observed in 3 patients (2.8%). The diagnostic performance was as follows: sensitivity, 90.1% (64/71); specificity, 97.3% (36/37); accuracy, 92.6% (100/108); positive predictive value, 98.5% (64/65); and negative predictive value, 83.7% (36/43). Multivariate analysis revealed that the number of punctures (odds ratio, 7.03; 95% confidence interval, 1.32–37.5; P = 0.023) and tumor type (odds ratio, 11.90; 95% confidence interval, 1.38–102.0; P = 0.024) were independent risk factors for inaccurate EUS-TA results. The diagnostic accuracy of EUS-TA for pancreatic ductal adenocarcinoma was 87.5% (14/16). No EUS-TA–related needle-tract seeding was observed in patients with pancreatic ductal adenocarcinoma during the observation period. Conclusions: EUS-TA for SPLs ≤10 mm showed adequate diagnostic accuracy and was safe for use with rapid on-site specimen evaluation in all cases.

28 September 2023 in Endoscopic Ultrasound
Verified
Journal Article
Open access
TKTakehiko Koga
Takehiko Koga
Susumu HijiokaSusumu Hijioka
Susumu Hijioka
YNYoshikuni Nagashio
Yoshikuni Nagashio
YMYuta Maruki
Yuta Maruki
KMKosuke Maehara
Kosuke Maehara
Takuji OkusakaTakuji Okusaka
Takuji Okusaka
Background and Objectives: During EUS–guided choledochoduodenostomy (EUS-CDS), fistula dilation before stent insertion is associated with adverse events (AEs), such as bile leakage and peritonitis. We hypothesized that EUS-CDS without fistula dilation using a novel self-expandable metal stent (SEMS) with a thin delivery system could overcome this problem, and we conducted this study to evaluate its feasibility and safety. Methods: This was an open-label, single-arm, phase II study at a single institution. We planned EUS-CDS without fistula dilation using a fully covered SEMS with a 5.9-Fr delivery system for unresectable malignant distal biliary obstruction. The primary outcome was overall technical success. Secondary outcomes were technical success without fistula dilation, procedure time, functional success, time to recurrent biliary obstruction, and AEs. The planned sample size was 25 patients. Results: In total, 24 patients were included in this study. In 21 patients, EUS-CDS was performed as primary drainage. The overall technical success rate was 100% (24 of 24 patients). The technical success rate without fistula dilation was 96% (23 of 24). The median procedure time was 16 min (range, 10–66 min). The functional success rate was 96% (23 of 24). The median time to recurrent biliary obstruction was 148 days (95% confidence interval, 29–266 days). There were no procedure-related AEs. Furthermore, computed tomography immediately after the procedure showed no leakage of contrast medium into the abdominal cavity in any patient. Conclusions: EUS–guided choledochoduodenostomy without fistula dilation using a fully covered SEMS with a 5.9-Fr delivery system is feasible with a high probability and can be achieved quickly while effectively preventing bile leakage and peritonitis.